Business Context and Reporting Period
This Form 8-K Current Report was filed by Kura Oncology, Inc. on June 4, 2021, covering events occurring on June 3, 2021. The filing addresses changes to the Board of Directors, specifically the resignation of a director and the appointment of a new director.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Director Resignation: Robert E. Hoffman tendered his resignation as a member of the Board of Directors and all committees, effective August 3, 2021.
- Director Appointment: Carol A. Schafer was appointed as a Class II director, a member of the Audit Committee, and Chairperson of the Audit Committee (effective upon Mr. Hoffman's resignation).
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for the newly appointed director, Carol A. Schafer, under the Company's Non-Employee Director Compensation Policy:
- Cash Retainers: $40,000 annual retainer for Board service, $7,500 additional for Audit Committee membership, and $7,500 additional for serving as Chairperson of the Audit Committee.
- Equity Grants: An initial option to purchase 46,000 shares of common stock, vesting annually over three years. Future automatic annual grants of 23,000 shares are provided on the date of each annual meeting, vesting in full one year after the grant date.
- Change in Control: All option grants vest in full in the event of a change in control.
The filing does not contain financial guidance, outlook, or discussion of risks and contingencies beyond standard governance disclosures.
Investor Verification Checklist
- Verify the effective date of Robert E. Hoffman's resignation (August 3, 2021) and the transition of Audit Committee Chair duties.
- Confirm the vesting schedule and total share count for Carol A. Schafer's equity grants (46,000 initial shares + 23,000 annual shares).
- Review the attached Press Release (Exhibit 99.1) for additional context on the Board's strategic direction.
- Check subsequent filings for any financial updates, as this 8-K contains no financial performance data.